PCAC, July 23–24 2026: the peptide meeting agenda
Seven peptides, two days, one advisory vote that decides nothing on its own. Here's the agenda — and what actually happens next.
Last reviewed July 14, 2026 · Updated after every FDA action · Not legal or medical advice
What this meeting actually does
The Pharmacy Compounding Advisory Committee is an independent panel that advises the FDA. Over two days it reviews whether seven peptides belong on the 503A Bulks List — the list that lets a licensed pharmacy compound a substance that has no USP monograph and isn't part of an FDA-approved drug.
The committee votes on recommendations. It does not make law. The FDA isn't bound by the outcome, and no substance reaches the list without a separate formal rulemaking process afterward. Nothing you can order changes on July 24.
The agenda
Nominators present first; open public hearing sessions run across both days.
Seven substances, fourteen nominations — each peptide is reviewed as two separate entries, free base and acetate, because salt forms can behave differently and are evaluated independently.
The details
FDA White Oak Campus, Silver Spring, Maryland. A virtual attendance option is available.
FDA-2025-N-6895 on regulations.gov. The public comment window closed July 9, 2026. Comments filed before then went to committee members ahead of the meeting.
FDA publishes its scientific briefing documents at least two business days before the meeting.
What the committee is looking at
We break down how each factor applies to BPC-157 and TB-500, and what each possible outcome would mean →
Three steps, and the vote is only the second one
The FDA removed these substances from Category 2. That lifted an earlier restriction. It was not approval, and it did not authorize compounding.
The committee reviews and recommends. Advisory only. The FDA is not bound by it.
Only a formal FDA rulemaking process can actually add a substance to the 503A list. That step takes months, not days.
Wondering where BPC-157 stands right now? →
What we'll post, and when
After the meeting closes on July 24, we'll post the committee's recommendation for each of the seven substances and update every row on the status board above — including the plain-English verdict for each one.
If a recommendation is positive, we'll also say plainly what it does not mean: that the FDA still has to act, and that nothing is orderable until a licensed clinician can prescribe it through a compliant pharmacy. We won't market any of these compounds before that's true.
Get the outcome when it postsWhere these seven stand today
Two signals, kept separate: the regulatory status, and what it means for you.
See the full tracker and the changelog →
Compounded, not FDA-approved. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not reviewed by the FDA for safety, effectiveness, or manufacturing the way approved drugs are. They are not the same as brand-name products, and they're only appropriate when a licensed clinician determines FDA-approved options don't fit your situation.
You don't have to wait on a committee
If you came here for recovery, energy, longevity or weight, there are compounded therapies a licensed clinician can prescribe today where they're clinically appropriate — matched to your goal, your health history, and your state. Two minutes tells you what you're eligible for. Nothing to pay to find out.
Questions people ask
What is PCAC?
The Pharmacy Compounding Advisory Committee is an independent panel of scientific and medical experts that advises the FDA on bulk drug substances — the raw ingredients licensed 503A compounding pharmacies work with. It reviews evidence and makes recommendations. It doesn't make law.
Which peptides are reviewed on which day?
July 23: BPC-157, KPV, TB-500 and MOTS-c. July 24: Emideltide (DSIP), Semax and Epitalon. Each is reviewed in both free base and acetate forms.
Can I attend or submit a comment?
The meeting is public, held at FDA's White Oak Campus in Silver Spring, Maryland, with a virtual option. The written comment docket (FDA-2025-N-6895) closed on July 9, 2026, so new written comments won't reach committee members before the meeting.
Does a positive vote mean BPC-157 becomes available?
No. The recommendation is advisory and the FDA isn't bound by it. Even a positive recommendation requires a separate formal rulemaking process before a substance can be added to the 503A list — and separately, a licensed clinician has to be able to prescribe it through a compliant pharmacy before anyone should offer it to you.
When will the FDA actually decide?
There's no fixed date. Rulemaking runs on its own timeline and typically takes many months. We'll post each status change here, dated, as it happens.
What can a clinician prescribe right now?
Depending on your health history and your state, a licensed clinician may prescribe compounded semaglutide or tirzepatide, sermorelin, NAD+ and B12, among others. These are compounded and not FDA-approved. The eligibility check shows what applies to you before anyone charges you anything.